For Leukemia
- Trial 20-562: A phase 1, open label dose-escalation and dose-expansion study to evaluate the safety, expansion, persistence and clinical activity of UCART22 (allogeneic engineered T-cells expressing anti-CD22 chimeric antigen receptor) in patients with relapsed or refractory CD22+ B-cell acute lymphoblastic leukemia (B-ALL)
Principal Investigator: Daniel DeAngelo, MD PhD - Trial 23-534: A phase 1 study of cytokine-induced memory-like (CIML) NK cells with venetoclax as consolidation therapy in AML
Principal Investigator: Evan Chen, MD
For more information, contact our Adult Leukemia Program.
For Lymphoma
- Trial 21-124: A multi-center single arm phase II study to evaluate the safety and efficacy of genetically engineered autologous cells expressing anti-CD20 and anti-CD19 specific chimeric antigen receptor in subjects with relapsed and/or refractory diffuse large B cell lymphoma
Principal Investigator: Caron Jacobson, MD, MMSc - Trial 22-467: An adaptive phase 3, randomized, open-label, multicenter study to compare the efficacy and safety of axicabtagene ciloleucel versus standard of care therapy as first-line therapy in subjects with high-risk large B-cell lymphoma
Principal Investigator: Caron Jacobson, MD, MMSc
For more information, contact our Adult Lymphoma Program.
For Multiple Myeloma
- Trial 23-696: A phase 1, multicenter, open-label study to evaluate the safety and preliminary efficacy of BMS-986393 in novel combinations in participants with relapsed and/or refractory multiple myeloma and determine the recommended dose for each add-on investigational component (phase 1 GPRC5D combo)
Principal Investigator: Omar Nadeem, MD - Trial 24-044: A phase 2, open-label, multicenter study of arlocabtagene autoleucel (BMS-986393), a GPRC5D-directed CAR T cell therapy in adult participants with relapsed or refractory multiple myeloma (QUINTESSENTIAL)
Principal Investigator: Omar Nadeem, MD - Trial 24-626: A phase 1, open-label, dose-finding study of BMS-986453, dual targeting BCMAxGPRC5D chimeric antigen receptor t cells, in participants with relapsed and/or refractory multiple myeloma
Principal Investigator: Clifton Mo, MD
For more information, contact our Multiple Myeloma Program.
For Solid Tumors
- Trial 22-395: A phase 1 multicenter study evaluating the safety and tolerability of GCC19CART in subjects with relapsed or refractory metastatic colorectal cancer (CARAPIA-1)
Principal Investigator: Benjamin Schlechter, MD - Trial 23-158: A first in human dose escalation and cohort expansion study of DLL3-directed chimeric antigen receptor T-cells in subjects with extensive stage small cell lung cancer
Principal Investigator: Jacob Sands, MD - Trial 23-317: An open-label, phase 1, multicenter study to evaluate the safety and preliminary anti-tumor activity of NT-175 in human leukocyte antigen-A*02:01-positive adult subjects with unresectable, advanced and/or metastatic solid tumors that are positive for the TP53 R175H mutation
Principal Investigator: Rishi Surana, MD, PhD - Trial 23-493: A phase 1b study of cytokine-induced memory like (CIML) natural killer (NK) cell therapy in recurrent ovarian cancer
Principal Investigator: Rebecca Porter, MD - Trial 23-583: A phase 2 trial of PD-L1 t-haNK, N-803 IL-15 superagonist (Anktiva), and cetuximab for immunotherapy-treated patients with advanced HNSCC (QUILT-505)
Principal Investigator: Glenn Hanna, MD - Trial 23-688: A phase 0 pilot study of memory-like natural killer (NK) cell immune therapy in patients with renal cell carcinoma or urothelial carcinoma
Principal Investigator: Wenxin Xu, MD
For more information, contact the relevant solid tumor treatment center.
Cell Manipulation Core Facility
For some cellular therapy products – especially in early phase clinical trials – our on-site Connell and O'Reilly Families Cell Manipulation Core Facility (CMCF) performs the primary cell manufacturing of genetically engineered products. For other cellular therapy products, cells are primarily manufactured at an outside commercial facility and the CMCF oversees the process of collecting the cells, shipment to the offsite commercial facility, return of the processed cells, and release for patient treatment.